Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Green synthesis of zinc oxide nanoparticles using Cassia absus leaf extract and evaluation of their biofertilizer potential and in vitro antibacterial activity against phytopathogens.

Discover nano·2026
Same author

A Mechanistic and Analytical Study of a Magnetically Separable Fe<sub>3</sub>O<sub>4</sub>/g-C<sub>3</sub>N<sub>4</sub>/SWCNT Photocatalyst: A Kinetic, GC-MS Degradation Pathways and AAS Leachate Analysis.

Luminescence : the journal of biological and chemical luminescence·2026
Same author

Risk of recurrent ischemic stroke after non-cardioembolic ischemic stroke in England and Denmark.

Journal of neurology·2026
Same author

Antithrombotic therapy, vascular events and mortality after non-cardioembolic ischaemic stroke: a nationwide hospital-based cohort study in Japan.

Stroke and vascular neurology·2026
Same author

Oral health status of NCC cadets in Uttar Pradesh: A cross-sectional study.

Bioinformation·2026
Same author

Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial.

Stroke·2026
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Combination therapy for dyslipidemia.

Mukul Sharma1

  • 1Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. msharma@Ottawahospital.on.ca

Current Opinion in Cardiology
|August 12, 2011
PubMed
Summary
This summary is machine-generated.

Combination therapies, including statins with ezetimibe or niacin, may further reduce cardiovascular risk in patients not reaching lipid targets with statin monotherapy alone. Evidence supports their use when maximal statin doses are insufficient.

Related Experiment Videos

Last Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Lipidology

Background:

  • Residual cardiovascular risk persists despite statin therapy.
  • Combination therapies are explored to further mitigate this risk.

Purpose of the Study:

  • To review the efficacy of combination therapies in managing dyslipidemia and cardiovascular risk.
  • To evaluate recent clinical trial findings on lipid-lowering combination treatments.

Main Methods:

  • Review of recent clinical trials investigating combination lipid-lowering therapies.
  • Analysis of trial outcomes regarding lipid profiles and clinical events.

Main Results:

  • Previous trials showed lipid profile improvements but not clinical superiority over statin monotherapy.
  • The Study of Heart and Renal Protection (SHARP) trial demonstrated benefit with ezetimibe/simvastatin.
  • The AIM-HIGH trial of statin/niacin was halted for futility.
  • Combining statins with niacin and ezetimibe significantly enhances lipid-lowering effects.

Conclusions:

  • Potent statin initiation and titration remain the cornerstone of lipid management.
  • Combination therapies are valuable for patients not achieving lipid goals on maximal statin doses.